Bluestar Adisseo Co

Chart & Performance

D1W1MN

P/E

22.20

P/S

1.72

EPS

0.45

Div Yield, %

0.60%

Shrs. gr., 5y

—

Rev. gr., 5y

6.88%

Revenues

15.53b

+17.83%

Net income

1.20b

+2,208.66%

CFO

2.94b

+6.53%

Dividend

Aug 13, 20240.06 CNY/sh

Profile

Bluestar Adisseo Company engages in the research, development, production, and sale of feed additives for animal nutrition worldwide. The company's products include Rhodimet, a methionine solution for monogastric animals that is available in solid and liquid forms, such as Rhodimet NP99 and Rhodimet AT88; nutrition solutions comprising Smartamine and MetaSmart for amino acid balancing in lactating dairy cow ration formulation, as well as for dairy cows and other ruminants; and Microvit, a range of vitamins for the feed industry. It also offers Rovabio, a range of enzyme preparations that enhance the digestibility of raw materials from vegetal origin for animals, poultry, and hogs; and Selisseo 2% Se, a source of organic selenium that is based on seleno-hydroxy-methionine for use in animal feed. In addition, the company provides AdiSodium, a source of chloride-free sodium that offers a solution for dietary electrolyte balance in monogastric feeds and supplies sulphur in assimilated form to ruminant feeds; and Alterion for enhancing the animal intestinal micro ecological environment and the production performance of animal. Further, it offers PNE, a service based on NIR technology to predict the nutritional quality of the raw materials used in feed; DiM, a service and assistance program for Rhodimet AT88 applications; and E-lab, a web service that allows customers to post analytical requests and identify samples prior to shipping them to Adisseo laboratory. The company was founded in 1939 and is based in Beijing, China. Bluestar Adisseo Company is a subsidiary of China National Bluestar (Group) Co., Ltd.

URL

http://www.bluestar-adisseo.com/

IPO date

Apr 20, 2000

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	15,534,275 17.83%	13,183,749 -9.26%	14,529,016 12.90%
Cost of revenue	13,540,078	11,791,768	12,203,888
Unusual Expense (Income)
NOPBT	1,994,197	1,391,981	2,325,127
NOPBT Margin	12.84%	10.56%	16.00%
Operating Taxes	369,038	11,757	291,064
Tax Rate	18.51%	0.84%	12.52%
NOPAT	1,625,159	1,380,223	2,034,064
Net income	1,204,326 2,208.66%	52,166 -95.82%	1,246,680 -15.29%
Dividends	(281,893)	(525,354)	(477,378)
Dividend yield	0.84%	2.45%	2.15%
Proceeds from repurchase of equity			(1,568,817)
BB yield			7.08%
Debt
Debt current	54,453	995,400	1,138,366
Long-term debt	1,554,035	1,416,700	1,406,687
Deferred revenue	138,005	146,913	147,452
Other long-term liabilities	799,329	883,559	557,376
Net debt	342,709	245,209	778,003
Cash flow
Cash from operating activities	2,944,669	2,764,212	1,728,821
CAPEX	(1,623,039)	(1,447,094)	(1,542,290)
Cash from investing activities	(1,634,245)	(1,855,053)	(1,800,536)
Cash from financing activities	(1,017,033)	(797,817)	(1,163,860)
FCF	1,837,418	2,021,485	157,895
Balance
Cash	1,265,779	1,005,228	796,360
Long term investments		1,161,663	970,690
Excess cash	489,065	1,507,703	1,040,600
Stockholders' equity	14,832,308	13,863,866	14,952,834
Invested Capital	17,312,301	16,645,902	16,738,053
ROIC	9.57%	8.27%	12.92%
ROCE	10.82%	7.35%	12.55%
EV
Common stock shares outstanding	2,681,901	2,681,901	2,681,901
Price	12.55 56.88%	8.00 -3.15%	8.26 -32.95%
Market cap	33,657,861 56.88%	21,455,210 -3.15%	22,152,505 -32.95%
EV	34,027,962	21,728,359	22,949,753
EBITDA	3,567,500	3,117,011	3,646,530
EV/EBITDA	9.54	6.97	6.29
Interest	83,520	134,147	43,482
Interest/NOPBT	4.19%	9.64%	1.87%